Search results for "Riba"

showing 10 items of 371 documents

« Au nom du père ou les “autobiographies” de ceux qui ne dessinent pas (Altarriba, Gallardo, Spiegelman, Tardi) »

2015

International audience; Antonio Altarriba, Miguel Angel Gallardo, Art Spiegelman ou encore Jacques Tardi sont autant d'auteurs qui ont dessiné l'autobiographie de leur père. Ces égodocuments, qui sont des oeuvres en collaboration, peuvent-ils encore être qualifiés d'autobiographies ? Faut-il parler d'allobiographies ? d'altrobiographies ? Par ailleurs, ces autobiographies père-fils ajoutent une nouvelle strate contractuelle à ce genre qui n'en manquait déjà pas : celle du modèle maussien du don et du contre-don.

AltarribaMaussGallardocomics[SHS.ART] Humanities and Social Sciences/Art and art historyTardi[SHS.ART]Humanities and Social Sciences/Art and art history[ SHS.ART ] Humanities and Social Sciences/Art and art historyMausAutobiographySpiegelman
researchProduct

AUTOBIO-GRAPHISMES

2015

Autobio-graphismes, premier ouvrage en langue française dédié intégralement à l'analyse de l'autobiographie dans la bande dessinée, brosse une cartographie de cette pratique devenue caractéristique de la bande dessinée actuelle aux Etats-Unis et en Europe.

Altarribabande dessinéeautobiographiecomics[SHS.ART] Humanities and Social Sciences/Art and art history[SHS] Humanities and Social SciencesautobiographySpiegelman
researchProduct

Cribado de alteraciones visuales (parte 2)

2015

En el presente trabajo se revisan y actualizan las recomendaciones de PrevInfad sobre el cribado de alteraciones visuales en la infancia. Se analizan los beneficios en salud de la deteccion precoz, la validez y seguridad de las pruebas de cribado, la efectividad del tratamiento y los posibles riesgos de la deteccion precoz y el tratamiento de los problemas detectados. PrevInfad recomienda incluir la inspeccion ocular y la prueba del reflejo rojo en las visitas de salud de los primeros seis meses de vida, asi como la deteccion de alteraciones visuales (ambliopia, estrabismo y errores de refraccion) a la edad de 3-5 anos. La evidencia para evaluar el balance entre los beneficios y los riesgos…

AmbliopíaPediatrics Perinatology and Child HealthAlteraciones visualesCribadoAgudeza visual
researchProduct

Cribado de alteraciones visuales (parte 1)

2014

En el presente trabajo se revisan y actualizan las recomendaciones de PrevInfad sobre el cribado de alteraciones visuales en la infancia. Se analizan los beneficios en salud de la deteccion precoz, la validez y seguridad de las pruebas de cribado, la efectividad del tratamiento y los posibles riesgos de la deteccion precoz y el tratamiento de los problemas detectados. PrevInfad recomienda incluir la inspeccion ocular y la prueba del reflejo rojo en las visitas de salud de los primeros seis meses de vida, asi como la deteccion de alteraciones visuales (ambliopia, estrabismo y errores de refraccion) a la edad de 3-5 anos. La evidencia para evaluar el balance entre los beneficios y los riesgos…

AmbliopíaPediatrics Perinatology and Child HealthAlteraciones visualesCribadoAgudeza visual
researchProduct

Faldaprevir (BI 201335), BI 207127 and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results

2013

Background Faldaprevir (BI 201335) and deleobuvir (BI 207127) are direct-acting antiviral agents under development for the treatment of chronic HCV infection. This article describes the final results of the Phase Ib SOUND-C1 study that evaluated the interferon-free oral combination of faldaprevir, deleobuvir and ribavirin in 32 treatment-naive patients infected with HCV genotype 1. Methods Patients were randomized to receive deleobuvir 400 mg ( n=15) or 600 mg ( n=17) three times daily plus faldaprevir 120 mg once daily and weight-based ribavirin for 4 weeks. Interferon-free therapy was followed by response-guided faldaprevir plus pegylated interferon-α2a/ribavirin to week 24 or 48. Results…

Aminoisobutyric AcidsProline[SDV]Life Sciences [q-bio]610 Medicine & healthHepacivirusAntiviral AgentsDrug Administration SchedulePolyethylene GlycolsTherapy naive03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHcv genotype 1LeucineRibavirinMedicine2736 Pharmacology (medical)Pharmacology (medical)Oral therapy030304 developmental biologyPharmacology0303 health sciencesbusiness.industryRibavirinDeleobuvirInterferon-alpha2725 Infectious DiseasesHepatitis C ChronicViral LoadVirologyRecombinant Proteins3. Good healthThiazolesInfectious DiseasesTreatment Outcome10219 Clinic for Gastroenterology and Hepatology3004 PharmacologychemistryAcrylatesFaldaprevirQuinolines030211 gastroenterology & hepatologyBenzimidazolesDrug Therapy CombinationbusinessOligopeptides
researchProduct

The HCV Sicily Network: A web-based model for the management of HCV chronic liver diseases

2016

Epidemiological studies report that in Sicily reside about 30,000 citizens with a diagnosis of chronic hepatitis due to HCV. The availability of direct antiviral action (DAA) is a real therapeutic breakthrough, but the high cost of the therapeutic regimes limits their use and forced the National Health System to establish clinical priority for the treatment.The HCV Sicily Network is a web-based model of best medical practice, which was designed to improve the management and the treatment of HCV chronic hepatitis and cirrhosis. The network includes 41 centers and 84 gastroenterologists or infectivologists connected by a web platform that recorder the diagnosis and the clinic priority for the…

Antiviral AgentMaleInternetHepaciviruHepatitis C virusInterferon-alphaDirect antiviral agent drugs (DAA); Hepatitis C virus; Web-based network; Pharmacology (medical)HepacivirusHepatitis C ChronicMiddle AgedWeb-based network; Hepatitis C virus; Direct antiviral agent drugs (DAAAntiviral AgentsCommunity NetworksTreatment OutcomeAntiviral Agents; Drug Therapy Combination; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Internet; Male; Middle Aged; Ribavirin; Sicily; Treatment Outcome; Community NetworksRibavirinHumansDirect antiviral agent drugs (DAADrug Therapy CombinationSicilyWeb-based networkHuman
researchProduct

L' Avventura dei Mille

2010

La situazione del 1860 era un intreccio che in tutto e per tutto assomigliava a un canestro di granchi. In questo clima Garibaldi, nato per l’azione, decise d’agire, stimolando le voglie di un’intera generazione che trovò nella spedizione il crogiolo della sua formazione e fu poi dimenticata. Giuseppe Nodari, soldato adolescente dell’ancien régime asburgico, che indossando la camicia rossa era diventato un borghese moderno italiano, ne è stato un esempio assai chiaro. I suoi disegni, ritrovati dopo anni di oblio e pubblicati integralmente per la prima volta in questo libro, sono d’un interesse clamoroso: raccontano in presa diretta, come in un film, la spedizione da Quarto a Palermo e costi…

Arte storia Giuseppe Garibaldi Giuseppe Nodari Quarto Palermo Sicilia MilleSettore ICAR/13 - Disegno Industriale
researchProduct

Cietušais kriminālprocesa izpratnē

2019

Bakalaura darba temats ir “Cietušais kriminālprocesa izpratnē”. Cietušais kriminālprocesā ir persona, kurai ar noziedzīgu nodarījumu nodarīts kaitējums – fizisks, morāls vai mantisks. Bakalaura darba mērķis ir izprast cietušā jēdziena būtību kriminālprocesa ietvaros, kā arī to, kādā veidā cietusī persona var tikt atzīta par cietušo kriminālprocesā. Bakalaura darbā tiks pētīts arī ne tik sen ieviestu īpaši aizsargājamā cietušā institūtu un tā nozīmi kriminālprocesā. Mērķa sasniegšanai autore bakalaura darbā centās nošķirt jēdzienu “upuris” no jēdziena “cietušais” kriminālprocesa izpratnē. Tika pētīts kādas izmaiņas ir skārušas Kriminālprocesa likumu pēc Direktīvas 29/12/ES ieviešanas un kā š…

Atzīšana par cietušoCietušaisĪpaši aizsargājamais cietušaisJuridiskā zinātneUpurisCietušās personas griba
researchProduct

NOVEL COMPOSED GALACTOSYLATED NANODEVICES CONTAINING A RIBAVIRIN PRODRUG AS HEPATIC CELL-TARGETED CARRIERS FOR HCV TREATMENT

2013

In this paper, we describe the preparation of liver-targeted nanoparticles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of carbohydrate receptors in the liver (i.e., ASGPR in hepatocytes). These particles were obtained starting from a galactosylated phospholipid-polyaminoacid conjugate. This latter was obtained by chemical reaction of ALPHA, BETA -poly(N-2-hydroxyethyl) (2-aminoethylcarbamate)-DL-aspartamide (PHEA-EDA) with 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl) sodium salt (DPPE), and subsequent reaction with lactose, obtaining PHEA-EDA-DPPE-GAL copolymer. To enhance the entrapment into obtained nanostructures, a hydroph…

Biomedical EngineeringPharmaceutical ScienceMedicine (miscellaneous)NanoparticleBioengineeringAntiviral AgentsDiffusionNon-competitive inhibitionNanocapsulesMaterials TestingRibavirinHumansGeneral Materials ScienceProdrugschemistry.chemical_classificationGalactoseHep G2 CellsProdrugCarbohydrateVirologyCombinatorial chemistryHepatitis CIn vitroGalactosylated Nanoparticles Hepatic Cell-Targeted Carriers Active Targeting Ribavirin Tripalmitate Hepatitis C.EnzymechemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryConjugate
researchProduct

HCV genotype 5: an orphan virus

2013

HCV genotype 5 (HCV-5) is the least known HCV genotype. It is found mainly in South Africa and in restricted areas of Belgium, Spain, France, Syria and Greece. Sporadic cases are reported worldwide. The main modes of transmission are blood transfusion and iatrogenic causes. Little is known about its origin, but various studies have elucidated its spread worldwide. In endemic areas, patients infected with HCV-5 are on average older and have a higher viral load and more advanced fibrosis than those infected with non-HCV-5 genotypes. The current standard of care for HCV-5 chronic infection is 48 weeks of dual therapy with pegylated interferon plus ribavirin. ‘Favourable’ Il28B polymorphisms a…

Blood transfusionGenotypemedicine.medical_treatmentHepacivirusAntiviral Agentschemistry.chemical_compoundPegylated interferonGenotypemedicinePrevalenceHumansPharmacology (medical)PharmacologyTransmission (medicine)business.industryRibavirinvirus diseasesHepatitis Cmedicine.diseaseHepatitis Cdigestive system diseasesChronic infectionInfectious DiseasesTreatment OutcomechemistryImmunologyHost-Pathogen InteractionsbusinessViral loadmedicine.drug
researchProduct